Puerto Rico Medicaid spending on GLP-1 drugs

How much did Puerto Rico Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $51.8 million for GLP-1 drugs paid through Puerto Rico Medicaid in 2025, across at least 48,732 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 37 rows of 148, so these figures are floors.

Pharmacies were reimbursed at least $11.2 million for GLP-1 drugs paid through Puerto Rico Medicaid in 2026 (quarter 1 only, as posted so far), across at least 10,786 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 8 rows of 25, so these figures are floors.

By year and ingredient

2023at least $81,851SuppressedSuppressedat least $3,206,426Suppressed$47,241at least $3,335,517
2024at least $66,653at least $1,295,627Suppressed$16,436,285Suppressedat least $31,222at least $17,829,786
2025at least $874,770at least $22,835,865Suppressed$28,111,999SuppressedSuppressedat least $51,822,634
2026 (Q1)at least $97,308at least $495,296Suppressed$10,641,920No dataSuppressedat least $11,234,524

By product, 2025

Ozempicat least $247,108at least 2414 of 14
RybelsusSuppressedSuppressed2 of 2
Wegovyat least $627,662at least 4525 of 19
Mounjaroat least $696,553at least 62810 of 28
Zepboundat least $22,139,312at least 19,8035 of 42
Liraglutide (generic name listing)SuppressedSuppressed2 of 2
VictozaSuppressedSuppressed3 of 3
Trulicity$28,111,99927,6080 of 32
BydureonSuppressedSuppressed2 of 2
SoliquaSuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $8,183,759at least 7,82311 of 35
Q2 2025at least $10,953,139at least 10,3599 of 36
Q3 2025at least $14,110,669at least 13,2529 of 38
Q4 2025at least $18,575,067at least 17,2988 of 39

By quarter, 2026 (posted so far)

Q1 2026at least $11,234,524at least 10,7868 of 25

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.